InternationalScored off the official board: an annual-only filer, so this data lags a domestic quarterly filer.

13F Pro Quality Score

25.9/100

Rank #2,646 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Email me the moment this company reports earnings
AI Research Report
Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.
Upgrade to Pro
Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

MESO Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for MESOBLAST LTD (MESO), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores MESO at 25.9/100 on a 32-signal composite quality model, placing it at rank #2,646 of 2,962 stocks — the bottom half of the AI-ranked universe. Top institutional holders of MESO by reported 13-F value include JANE STREET GROUP, CITADEL ADVISORS, MORGAN STANLEY, based on the most recent SEC filings. MESO trades on the Nasdaq exchange and files with the SEC under CIK 1345099. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MESO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for MESOBLAST LTD directly from SEC EDGAR. MESOBLAST LTD's 13F Pro composite quality score has ranged between 25 and 38 since 2026, currently 25.9 — a stable long-term trajectory across 48 quarterly and live scoring snapshots.

Fun facts about MESOBLAST LTD

Quirks, history, and lore behind MESO — the kind of stuff that makes a stock memorable.

  • 1
    The Basics
    An Australian biotech company listed on Nasdaq focused on cellular medicines derived from adult mesenchymal stem cells.
  • 2
    The Numbers
    A small-cap clinical-stage company that has burned through hundreds of millions in R&D over the years — revenue is minimal while it awaits regulatory approvals.
  • 3
    The History
    Founded around 2004 and spun out of pioneering stem-cell research, the company has spent decades trying to turn mesenchymal lineage cells into approved therapies.
  • 4
    The Secret
    Its lead programs target some of medicine's hardest problems — including graft-versus-host disease and heart failure — conditions with few good treatment options.
  • 5
    The Lore
    The FDA famously issued a Complete Response Letter for its lead product, sending the stock crashing — but the company fought back and resubmitted, refusing to die.
  • 6
    The Giveaway
    Its name is practically a portmanteau of its science: meso for mesenchymal, blast for the progenitor cells it harnesses — an Aussie stem-cell pioneer trading under ticker MESO.
▶ Think you know your stocks? Play the Daily Ticker
Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+191.4% YoY
$17.2MFY 2025
FY22 $10.2MFY23 $7.5MFY24 $5.9MFY25 $17.2M

Total Assets

+17.3% YoY
$784.7MFY 2025
FY22 $662.1MFY23 $669.4MFY24 $669.2MFY25 $784.7M

Total Debt

FY 2025
FY22 $5.0MFY23 FY24 FY25

Get alerted when MESO's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for MESOBLAST LTD including:

SEC EDGAR filings (10-K, 10-Q, 8-K)
XBRL financial facts (revenue, EPS, margins)
Insider transactions (Form 4)
Institutional 13F holdings
Quality rankings (32 signals)
AI analyst debates & daily meetings
Historical financial trends
Peer comparison & sector analysis

Companies Similar to MESO

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

IVA

Inventiva S.A.

29
AI score
Similar quality profile · 3 shared holders
GURE

GULF RESOURCES, INC.

34
AI score
Similar quality profile
KOSS

KOSS CORP

36
AI score
Similar quality profile
AVXL

ANAVEX LIFE SCIENCES CORP.

25
AI score
Similar quality profile · 3 shared holders
CRGO

Freightos Ltd

31
AI score
Similar quality profile · 1 shared holders
CWD

CaliberCos Inc.

15
AI score
Similar quality profile
FIRY

Firy Inc.

19
AI score
Similar quality profile
LPL

LG Display Co., Ltd.

34
AI score
Similar quality profile · 1 shared holders

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

Put MESO on your watchlist

Track score changes the day MESOBLAST LTD files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Is MESO a good stock to buy?

13F Pro's AI-powered analysis of MESOBLAST LTD (MESO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MESO are available on the MESO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. MESO is classified as a large company.

Which hedge funds own MESO?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MESO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of MESOBLAST LTD's investment landscape.